Full Press Release Details
BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences:
H.C. Wainwright 28th Annual Global Investment Conference Format: On-demand presentation and one-on-one meetings Presentation available beginning Friday, September 11, 2026 at 7:00 AM ET One-on-one meetings: Tuesday, September 15, 2026
Morgan Stanley 24th Annual Global Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Monday, September 14, 2026 Time: 5:35 PM ET
Live and on-demand webcasts of each event can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. Each webcast will be archived and available for replay for 90 days following the live event.
About Fractyl Health Fractyl is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.